FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2950231374> ?p ?o ?g. }

• W2950231374 endingPage "861" @default.
• W2950231374 startingPage "847" @default.
• W2950231374 abstract "The binding of lead compounds and drugs to human serum albumin (HSA) is a ubiquitous problem in drug discovery since it modulates the availability of the leads and drugs to their intended target, which is linked to biological efficacy. In our continuing efforts to identify small molecule αVβ3 and αVβ5 dual antagonists, we recently reported indoles 2–4 as potent and selective αVβ3/αVβ5 antagonists with good oral bioavailability profile. In spite of subnanomolar binding affinity of these compounds to human αVβ3 and αVβ5 integrins, high HSA binding (96.5–97.3%) emerged as a limiting feature for these leads. Structure–activity HSA binding data of organic acids reported in the literature have demonstrated that the incorporation of polar groups into a given molecule can dramatically decrease the affinity toward HSA. We sought to apply this strategy by examining the effects of such modifications in both the central core constrain and the substituent β to the carboxylate. Most of these derivatives were prepared in good yields through a cesium fluoride-catalyzed coupling reaction. This reaction was successful with a variety of nitrogen-containing scaffolds (20, 33, and 43) and selected acetylenic derivatives (16, 19, and 34). Among the compounds synthesized, the 3-[5-[2-(5,6,7,8-tetrahydro [1,8]naphthyridin-2-yl)ethoxy]indol-1-yl]-3-[5-(N,N-dimethylaminomethyl)-3-pyridyl]propionic acid (25) was found to be the most promising derivative within this novel series with a subnanomolar affinity for both αvβ3 and αvβ5 (IC50 = 0.29 and 0.16 nM, respectively), similar to our initial lead receptor antagonists 2–4, and exhibiting a low HSA protein binding (40% bound, Kd = 1.1 ± 0.4 × 103 μM) and an improved in vitro stability profile toward human and mouse microsomes (99.9% and 98.7% remaining after 10 min). Moreover, the selectivity of 25 toward α5β1 and IIbIIIa integrins was perfectly maintained when compared to the parent leads 2–4. Thus, compound 25 was selected as a new lead with improved drug-like properties for further evaluations in the field of oncology and osteoporosis." @default.
• W2950231374 created "2019-06-27" @default.
• W2950231374 creator A5009088679 @default.
• W2950231374 creator A5027528883 @default.
• W2950231374 creator A5029802130 @default.
• W2950231374 creator A5038281616 @default.
• W2950231374 creator A5043951728 @default.
• W2950231374 creator A5047937092 @default.
• W2950231374 creator A5061998470 @default.
• W2950231374 creator A5062210953 @default.
• W2950231374 creator A5080735476 @default.
• W2950231374 date "2006-07-01" @default.
• W2950231374 modified "2023-09-26" @default.
• W2950231374 title "Novel potent and selective αvβ3/αvβ5 integrin dual antagonists with reduced binding affinity for human serum albumin" @default.
• W2950231374 cites W1576773659 @default.
• W2950231374 cites W176130659 @default.
• W2950231374 cites W1973238993 @default.
• W2950231374 cites W1978340181 @default.
• W2950231374 cites W1989075697 @default.
• W2950231374 cites W1992119129 @default.
• W2950231374 cites W1992221074 @default.
• W2950231374 cites W2001753204 @default.
• W2950231374 cites W2011472036 @default.
• W2950231374 cites W2016636097 @default.
• W2950231374 cites W2025094806 @default.
• W2950231374 cites W2029245342 @default.
• W2950231374 cites W2039317622 @default.
• W2950231374 cites W2040690180 @default.
• W2950231374 cites W2049588022 @default.
• W2950231374 cites W2051135339 @default.
• W2950231374 cites W2065954013 @default.
• W2950231374 cites W2068052839 @default.
• W2950231374 cites W2068681478 @default.
• W2950231374 cites W2080719869 @default.
• W2950231374 cites W2081971948 @default.
• W2950231374 cites W2087172103 @default.
• W2950231374 cites W2093654063 @default.
• W2950231374 cites W2096868396 @default.
• W2950231374 cites W2104713336 @default.
• W2950231374 cites W2113267611 @default.
• W2950231374 cites W2125391482 @default.
• W2950231374 cites W2134649580 @default.
• W2950231374 cites W2141134845 @default.
• W2950231374 cites W2161678162 @default.
• W2950231374 cites W2172994560 @default.
• W2950231374 cites W2174408153 @default.
• W2950231374 cites W2241099034 @default.
• W2950231374 cites W286388493 @default.
• W2950231374 cites W2949549974 @default.
• W2950231374 cites W2952232260 @default.
• W2950231374 cites W4244550254 @default.
• W2950231374 cites W4322717319 @default.
• W2950231374 cites W87190817 @default.
• W2950231374 doi "https://doi.org/10.1016/j.ejmech.2006.03.008" @default.
• W2950231374 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16697080" @default.
• W2950231374 hasPublicationYear "2006" @default.
• W2950231374 type Work @default.
• W2950231374 sameAs 2950231374 @default.
• W2950231374 citedByCount "13" @default.
• W2950231374 countsByYear W29502313742013 @default.
• W2950231374 countsByYear W29502313742018 @default.
• W2950231374 countsByYear W29502313742021 @default.
• W2950231374 countsByYear W29502313742022 @default.
• W2950231374 crossrefType "journal-article" @default.
• W2950231374 hasAuthorship W2950231374A5009088679 @default.
• W2950231374 hasAuthorship W2950231374A5027528883 @default.
• W2950231374 hasAuthorship W2950231374A5029802130 @default.
• W2950231374 hasAuthorship W2950231374A5038281616 @default.
• W2950231374 hasAuthorship W2950231374A5043951728 @default.
• W2950231374 hasAuthorship W2950231374A5047937092 @default.
• W2950231374 hasAuthorship W2950231374A5061998470 @default.
• W2950231374 hasAuthorship W2950231374A5062210953 @default.
• W2950231374 hasAuthorship W2950231374A5080735476 @default.
• W2950231374 hasConcept C107824862 @default.
• W2950231374 hasConcept C161624437 @default.
• W2950231374 hasConcept C185592680 @default.
• W2950231374 hasConcept C21951064 @default.
• W2950231374 hasConcept C2778597219 @default.
• W2950231374 hasConcept C2778689049 @default.
• W2950231374 hasConcept C55493867 @default.
• W2950231374 hasConcept C71240020 @default.
• W2950231374 hasConceptScore W2950231374C107824862 @default.
• W2950231374 hasConceptScore W2950231374C161624437 @default.
• W2950231374 hasConceptScore W2950231374C185592680 @default.
• W2950231374 hasConceptScore W2950231374C21951064 @default.
• W2950231374 hasConceptScore W2950231374C2778597219 @default.
• W2950231374 hasConceptScore W2950231374C2778689049 @default.
• W2950231374 hasConceptScore W2950231374C55493867 @default.
• W2950231374 hasConceptScore W2950231374C71240020 @default.
• W2950231374 hasIssue "7" @default.
• W2950231374 hasLocation W29502313741 @default.
• W2950231374 hasLocation W29502313742 @default.
• W2950231374 hasOpenAccess W2950231374 @default.
• W2950231374 hasPrimaryLocation W29502313741 @default.
• W2950231374 hasRelatedWork W1984744703 @default.
• W2950231374 hasRelatedWork W1989692008 @default.
• W2950231374 hasRelatedWork W1995030173 @default.
• W2950231374 hasRelatedWork W2076364111 @default.

• next